Recently acquired infection among HIV-seropositive donors in the US from 2010-2018.
Journal
Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
29
04
2020
revised:
03
08
2020
accepted:
03
08
2020
pubmed:
30
8
2020
medline:
30
6
2021
entrez:
30
8
2020
Statut:
ppublish
Résumé
Monitoring of transfusion-transmissible infections in the blood supply is essential for blood safety, as the donor population is not static, and changes in policy, donor behavior, or other factors could increase the risk of recipient infection. We assessed patterns of recently acquired HIV infection in US blood donors, including before and after the implementation of the 12-month deferral for men who have sex with men (MSM). A large convenience sample of donations from donors testing HIV-1 nucleic acid testing (NAT) and serology-reactive were further tested with the Sedia HIV-1 Limiting Antigen enzyme immunoassay. Samples were analyzed across available demographic and donation data to provide an assessment of recently acquired HIV infection in US blood donors from 2010 to 2018. Overall, 317 of 1154 (27.5%; 95% confidence interval, 24.9%-30.1%) donations from HIV NAT and serology-reactive donors had recently acquired HIV infection. There was no evidence of change in the percentages of recent HIV infection by year over the study period, either in all donors or in male donors, including after the MSM policy change. In multivariable logistic regression analysis, donors aged 24 years or younger were over 2.7 times more likely and repeat donors 2.2 times more likely to have recently acquired HIV infection compared to donors aged 55 years or older and first-time donors, respectively. Patterns of recently acquired HIV infection varied by demographics but not over time. These findings suggest no impact of the MSM policy change on recently acquired HIV infection in US blood donors.
Sections du résumé
BACKGROUND
Monitoring of transfusion-transmissible infections in the blood supply is essential for blood safety, as the donor population is not static, and changes in policy, donor behavior, or other factors could increase the risk of recipient infection. We assessed patterns of recently acquired HIV infection in US blood donors, including before and after the implementation of the 12-month deferral for men who have sex with men (MSM).
STUDY DESIGN AND METHODS
A large convenience sample of donations from donors testing HIV-1 nucleic acid testing (NAT) and serology-reactive were further tested with the Sedia HIV-1 Limiting Antigen enzyme immunoassay. Samples were analyzed across available demographic and donation data to provide an assessment of recently acquired HIV infection in US blood donors from 2010 to 2018.
RESULTS
Overall, 317 of 1154 (27.5%; 95% confidence interval, 24.9%-30.1%) donations from HIV NAT and serology-reactive donors had recently acquired HIV infection. There was no evidence of change in the percentages of recent HIV infection by year over the study period, either in all donors or in male donors, including after the MSM policy change. In multivariable logistic regression analysis, donors aged 24 years or younger were over 2.7 times more likely and repeat donors 2.2 times more likely to have recently acquired HIV infection compared to donors aged 55 years or older and first-time donors, respectively.
CONCLUSION
Patterns of recently acquired HIV infection varied by demographics but not over time. These findings suggest no impact of the MSM policy change on recently acquired HIV infection in US blood donors.
Types de publication
Clinical Trial
Journal Article
Multicenter Study
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
2340-2347Subventions
Organisme : U.S. Food and Drug Administration
ID : HHSF223201510149C
Informations de copyright
© 2020 AABB.
Références
AuBuchon JP. Safety of the blood supply in the United States: opportunities and controversies. Ann Intern Med. 1997;127:904-909.
Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American red Cross blood donor population. Transfusion. 2002;42:975-979.
Centers for Disease Control and Prevention. HIV transmission through transfusion - Missouri and Colorado. Morb Mortal Wkly Rep. 2010;59:1335.
Seed CR, Yang H, Lee JF. Blood safety implications of donors using HIV pre-exposure prophylaxis. Vox Sang. 2017;112:473-476.
Custer B, Stramer SL, Glynn S, Williams AE, Anderson SA. Transfusion-transmissible infection monitoring system: a tool to monitor changes in blood safety. Transfusion. 2016;56:1499-1502.
Duong YT, Qiu M, De AK, et al. Detection of recent HIV-1 infection using a new limiting-antigen avidity assay: potential for HIV-1 incidence estimates and avidity maturation studies. PLoS One. 2012;7:e33328.
Granade TC, Nguyen S, Kuehl DS, Parekh BS. Development of a novel rapid HIV test for simultaneous detection of recent or long-term HIV type 1 infection using a single testing device. AIDS Res Hum Retroviruses. 2013;29:61-67.
Wei X, Liu X, Dobbs T, et al. Development of two avidity-based assays to detect recent HIV type 1 seroconversion using a multisubtype gp41 recombinant protein. AIDS Res Hum Retroviruses. 2010;26:61-71.
US Food and Drug Administration. Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products: U.S. Department of Health and Human Services, 2015. https://www.fda.gov/files/vaccines,%20blood%20&%20biologics/published/Revised-Recommendations-for-Reducing-the-Risk-of-Human-Immunodeficiency-Virus-Transmission-by-Blood-and-Blood-Products-Guidance-for-Industry.pdf. Accessed November 18, 2019.
Sedia HIV-1 LAg-Avidity EIA: Sedia Biosciences Corporation, 2018. file:///C:/Users/311134/Downloads/LN-6039-09,+Package+Insert,+LAg+Avidity+EIA%20(3).pdf. Accessed November 20, 2019.
Duong YT, Kassanjee R, Welte A, et al. Recalibration of the limiting antigen avidity EIA to determine mean duration of recent infection in divergent HIV-1 subtypes. PLoS One. 2015;10:e0114947.
Hologic I. HOLOGIC Aptima HIV-1 Quant Assay, 2018. https://www.hologic.com/sites/default/files/2019-03/AW-13242_002_01_0.pdf. Accessed November 20, 2019.
US Census Bureau. Census regions and divisions of the United States: U.S. Department of Commerce economics and statistics administration. https://www2.census.gov/geo/pdfs/maps-data/maps/reference/us_regdiv.pdf. Accessed November 20, 2019.
Liebler CA, Porter SR, Fernandez LE, Noon JM, Ennis SR. America's churning races: race and ethnicity response changes between census 2000 and the 2010 census. Demography. 2017;54:259-284.
Core R. Team: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2019 Available from: https://www.R-project.org/.
Wickham H. ggplot2: Elegant Graphics for Data Analysis. New York, NY: Springer-Verlag, 2016 Available from: https://ggplot2.tidyverse.org.
Schupbach J. Viral RNA and p24 antigen as markers of HIV disease and antiretroviral treatment success. Int Arch Allergy Immunol. 2003;132:196-209.
Zhang W, Morshed MM, Noyan K, Russom A, Sönnerborg A, Neogi U. Quantitative humoral profiling of the HIV-1 proteome in elite controllers and patients with very long-term efficient antiretroviral therapy. Sci Rep. 2017;7:666.
Kassanjee R, Pilcher CD, Busch MP, et al. Viral load criteria and threshold optimization to improve HIV incidence assay characteristics. AIDS. 2016;30:2361-2371.
Kassanjee R, McWalter TA, Bärnighausen T, et al. A new general biomarker-based incidence estimator. Epidemiology. 2012;23:721-728.
Grebe E, Busch MP, Notari EP, et al. HIV incidence in US first-time blood donors and transfusion risk with a 12-month deferral for men who have sex with men. Blood. 2020. https://doi.org/10.1182/blood.2020007003. Online ahead of print.
Chiavetta J, Ennis M, Gula CA, et al. Test-seeking as motivation in volunteer blood donors. Transfus Med Rev. 2000;14:205-215.
Duquesnoy A, Danic B, Santos A, et al. Context and social perceptions of blood donation in donors found positive for human immunodeficiency virus in France. Transfusion. 2017;57:2240-2247.
Goncalez T, Sabino E, Sales N, et al. Human immunodeficiency virus test-seeking blood donors in a large blood bank in Sao Paulo, Brazil. Transfusion. 2010;50:1806-1814.
Goncalez TT, Sabino EC, Murphy EL, Chen S, Chamone DAF, McFarland W. Human immunodeficiency virus test-seeking motivation in blood donors, Sao Paulo, Brazil. Vox Sang. 2006;90:170-176.
Miranda C, Moreno E, Bruhn R, et al. Knowledge of HIV testing and attitudes towards blood donation at three blood centres in Brazil. Vox Sang. 2014;106:344-353.
Truong HH, Blatyta PF, Santos FM, et al. Blood donor test-seeking motivation and prior HIV testing experiences in Sao Paulo, Brazil. AIDS Behav. 2015;19:1574-1578.
Center for Biologics Research and Evaluation. Coronavirus (COVID-19) Update: FDA Provides Updated Guidance to Address the Urgent Need for Blood During the Pandemic. White Oak, MD: U.S. Department of Health and Human Services, 2020 https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-provides-updated-guidance-address-urgent-need-blood-during-pandemic. Accessed April 16, 2020.